Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Obecabtagene autoleucel (obe-cel), Obecabtagene autoleucel, AUTO1
obe-cel (AUTO1) · 5 trials · 5 indications
CRR is a composite endpoint
Percentage of patients receiving obe-cel who experience dose-limiting toxicities (DLTs)
Adverse event (AE) type, frequency, severity, and relationship with obe-cel and lymphodepletion of AEs
| Arm | Type | Description |
|---|---|---|
| Obe-cel | EXPERIMENTAL | - |
| Obecabtagene autoleucel (obe-cel) | EXPERIMENTAL | - |
| AUTO1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Obecabtagene autoleucel | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion |
| Obecabtagene autoleucel (obe-cel) | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion. |
| AUTO1 | BIOLOGICAL | Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells |
Inclusion Criteria: * Willing and able to give written informed consent for participation in the study or written informed consent signed by a legal guardian or representative * Ability and willingness to adhere to protocol's Schedule of Activities and other requirements * Participants must be 12 t...
Top 17 of 18 competitors
Obe-cel is an investigational cell therapy being studied in several conditions: lupus nephritis, systemic lupus erythematosus, progressive multiple sclerosis, and relapsed or refractory B cell acute lymphoblastic leukemia. It is also being evaluated in aggressive mature B-cell non-Hodgkin lymphoma. All of these uses remain in clinical development rather than routine clinical practice.
Obe-cel targets CD19, a protein found on the surface of B cells. It is a CD19-directed chimeric antigen receptor T cell therapy, meaning the patient's T cells are engineered to recognize and act on CD19-expressing cells. This binding-agent approach underlies its study in both B cell malignancies and B cell driven autoimmune conditions.
Obe-cel is developed by Autolus Therapeutics plc, which trades on the Nasdaq under the ticker AUTL. The company is the sponsor behind the clinical programs evaluating the therapy across autoimmune and hematologic indications.
Obe-cel is in Phase 2 development overall and is investigational, meaning it has not been established as an approved therapy. Its programs span Phase 1 and Phase 2 studies, with the Phase 2 work focused on severe, refractory systemic lupus erythematosus with active lupus nephritis.
Obe-cel is being studied in trials including NCT07053800 in severe refractory systemic lupus erythematosus with active lupus nephritis, NCT07139743 in refractory progressive forms of multiple sclerosis, NCT06333483 in severe refractory systemic lupus erythematosus, and NCT06173518 in pediatric relapsed or refractory B cell acute lymphoblastic leukemia and aggressive mature B-cell non-Hodgkin lymphoma.
Yes. Obe-cel, obecabtagene autoleucel, and AUTO1 all refer to the same investigational CD19-directed CAR T cell therapy from Autolus Therapeutics. Readers may encounter any of these names in trial listings, publications, or company materials, and they describe the same asset.